<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prophylaxis of invasive fungal infections in adults with hematologic malignancies</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prophylaxis of invasive fungal infections in adults with hematologic malignancies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prophylaxis of invasive fungal infections in adults with hematologic malignancies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Wingard, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Bow, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H564717498"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Invasive fungal infections are common in high-risk patients with hematologic malignancies, such as patients with acute leukemia receiving induction chemotherapy, and cause substantial morbidity and mortality. The risk for invasive fungal infections increases with the duration and severity of neutropenia, prolonged antibiotic use, and number of chemotherapy cycles.</p><p>Interest in antifungal prophylaxis for high-risk patients receiving chemotherapy has been prompted by the rising incidence of life-threatening invasive fungal infections among cancer patients [<a href="#rid1">1</a>], the difficulty in establishing the diagnosis early in the course of infection, and the recognition that treatment outcomes are poor if initiation of therapy is delayed.</p><p>The epidemiology and prophylaxis of invasive fungal infections in patients with hematologic malignancies will be discussed here. The epidemiology and prophylaxis of invasive fungal infections in hematopoietic cell transplant recipients are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients"</a>.)</p><p>Other important issues related to infections in patients with hematologic malignancies are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1153.html" rel="external">"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13951.html" rel="external">"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications", section on 'Initial regimen'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15674.html" rel="external">"Treatment and prevention of Fusarium infection"</a>.)</p><p></p><p class="headingAnchor" id="H564717505"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Both yeasts and molds cause serious invasive fungal infections in patients with hematologic malignancies. Prior to the routine use of antifungal prophylaxis, <em>Candida</em> spp accounted for the majority of fungal infections that occurred during neutropenia, followed by <em>Aspergillus</em> spp [<a href="#rid2">2-4</a>]. More recently, <em>Aspergillus</em> has surpassed <em>Candida</em> as a cause of invasive fungal infections in patients with hematologic malignancies, likely due to the use of antifungal prophylaxis targeting <em>Candida</em> spp [<a href="#rid5">5-7</a>]. Both pathogens are associated with substantial risk for mortality.</p><p>In an autopsy study of patients who died after prolonged neutropenic fever between 1966 and 1975, rising rates of fungal infection were noted [<a href="#rid2">2</a>]. Over half of the patients in this early series had <em>Candida</em> infections, which may have been effectively prevented with antifungal prophylaxis. For example, in one trial, fungal infections were documented in only 1 percent of patients receiving <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis who had persistent fevers despite receiving broad-spectrum antibiotics [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H564717552"><span class="h2">Candida infection</span><span class="headingEndMark"> — </span><em>Candida</em> is the most important yeast pathogen, accounting for most invasive yeast infections [<a href="#rid9">9,10</a>]. The incidence of invasive candidiasis in patients with hematologic malignancies has varied widely in different studies, likely due to differences in the underlying disease (eg, newly diagnosed, in remission, relapsed, or refractory to treatment), the duration of neutropenia, and the types of chemotherapy regimens used [<a href="#rid11">11</a>]. Rates of invasive <em>Candida</em> infection in patients with hematologic malignancies not receiving antifungal prophylaxis have ranged from 8 to 24 percent [<a href="#rid12">12-17</a>].</p><p>Although <em>Candida</em> is ordinarily a harmless colonizer of mucosal surfaces and skin, breeches in skin or mucosal integrity can lead to invasion of deep tissues and hematogenous dissemination. The portal of entry for this commensal organism is thought to be primarily the gastrointestinal tract in this patient population, with translocation occurring as a result of mucosal injury from cytotoxic chemotherapy. Candidemia is the most frequent clinical manifestation of invasive candidiasis. <em>Candida</em> is also a common fungal cause of central venous catheter-associated infections. Less commonly, <em>Candida</em> causes disseminated candidiasis, including chronic disseminated candidiasis (hepatosplenic candidiasis). (See  <a class="medical medical_review" href="/z/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)"</a>.)</p><p>Patients with acute leukemia are at highest risk for invasive candidiasis during the period of neutropenia that follows induction chemotherapy. Although <em>Candida albicans</em> accounts for about half of invasive <em>Candida</em> infections, patients with hematologic malignancies and hematopoietic cell transplant recipients are also at increased risk for infections caused by non-albicans <em>Candida</em> species (eg, <em>C. glabrata</em>, <em>C. tropicalis</em>) compared with other types of patients [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis", section on 'Prevalence of Candida species'</a>.)</p><p class="headingAnchor" id="H564717559"><span class="h2">Aspergillus infection</span><span class="headingEndMark"> — </span><em>Aspergillus</em> is the most common mold pathogen in patients with hematologic malignancies [<a href="#rid5">5</a>]. In patients with acute myelogenous leukemia (AML), the incidence of invasive aspergillosis has ranged from 2 to 28 percent, with most studies reporting rates between 5 and 10 percent [<a href="#rid11">11</a>]. In such patients, the risk varies according to the disease status; patients with relapsed or refractory AML receiving salvage chemotherapy are at the greatest risk, whereas newly diagnosed patients receiving induction chemotherapy are at lower risk. AML patients in remission who are receiving consolidation chemotherapy are at the lowest risk.</p><p>The usual portal of entry of this airborne organism is inhalation into the sinuses and respiratory tract. The most frequent manifestation of invasive aspergillosis is pneumonia. Pulmonary infiltrates due to <em>Aspergillus</em> typically consist of one or more nodules with or without surrounding ground-glass opacities (the halo sign), cavities, air-crescent signs, or focal airspace consolidation. Other manifestations include sinusitis, localized skin ulcers, subcutaneous nodules, cerebral infarction, and/or fulminant disseminated disease.</p><p><em>A. fumigatus</em> is the most common <em>Aspergillus</em> species to cause disease, but several other <em>Aspergillus</em> species also cause invasive disease. (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a>.)</p><p class="headingAnchor" id="H564717578"><span class="h2">Other fungal infections</span><span class="headingEndMark"> — </span>The agents of mucormycosis are the second most common cause of mold infections in patients with hematologic malignancies [<a href="#rid19">19,20</a>] but are infrequent overall at most centers. Mucormycosis can cause life-threatening rhino-orbital, pulmonary, cerebral, and/or disseminated infection [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)", section on 'Risk factors'</a>.)</p><p><em>Fusarium</em> spp and <em>Scedosporium</em> spp have also been reported in patients with hematologic malignancies. (See  <a class="medical medical_review" href="/z/d/html/2426.html" rel="external">"Mycology, pathogenesis, and epidemiology of Fusarium infection"</a> and  <a class="medical medical_review" href="/z/d/html/2424.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Scedosporium and Lomentospora infections"</a>.)</p><p><em>Pneumocystis </em>pneumonia (PCP) is an occasional fungal pathogen that occurs in patients with hematologic malignancies, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV"</a>.)</p><p>Although primary infection and reactivation infection with endemic fungi (histoplasmosis, blastomycosis, and coccidioidomycosis) is uncommon in patients with hematologic malignancies, these fungi should also be considered in patients with prolonged glucocorticoid use or other immunosuppression who have lived in or traveled to endemic areas. (See  <a class="medical medical_review" href="/z/d/html/2450.html" rel="external">"Pathogenesis and clinical features of pulmonary histoplasmosis"</a> and  <a class="medical medical_review" href="/z/d/html/2458.html" rel="external">"Mycology, pathogenesis, and epidemiology of blastomycosis"</a> and  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a>.)</p><p class="headingAnchor" id="H564717631"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H564717639"><span class="h2">Acute leukemia</span><span class="headingEndMark"> — </span>In patients with hematologic malignancies, the incidence of fungal infection (especially those caused by <em>Candida</em> or <em>Aspergillus</em> spp) rises after patients have experienced more than seven days of persistent fever and neutropenia [<a href="#rid22">22</a>]. The major risk factor for invasive candidiasis is receiving an intensive induction regimen for acute leukemia that causes severe oral and/or gastrointestinal mucosal injury. Other contributory risk factors are use of broad-spectrum antibiotics and presence of a central venous catheter.</p><p>Risk factors for invasive aspergillosis in patients with hematologic malignancies are advanced or refractory acute myelogenous leukemia or high-risk myelodysplastic syndrome, the need to administer multiple chemotherapy regimens to attempt to achieve remission, iron overload from multiple erythrocyte transfusions, chronic neutropenia before initiation of chemotherapy, and prior aspergillosis during previous treatment [<a href="#rid22">22-26</a>].</p><p class="headingAnchor" id="H564717671"><span class="h2">Other patients at risk</span><span class="headingEndMark"> — </span>Hematopoietic cell transplantation, particularly allogeneic HCT, confers substantial risk for invasive fungal infections. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients", section on 'Risk factors'</a>.)</p><p>Compared with patients with acute leukemia and HCT recipients, the risk for invasive fungal infections is lower in patients with chronic leukemias, lymphoma, and multiple myeloma, but invasive fungal infections do occur in such patients [<a href="#rid27">27</a>].</p><p><a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">Ibrutinib</a>, a Bruton tyrosine kinase inhibitor that causes hypogammaglobulinemia and inhibits B cell signaling, has been associated with invasive fungal infections, such as <em>Aspergillus</em> and <em>Cryptococcus</em> infections. Most of these cases have occurred in patients with chronic lymphocytic leukemia. (See  <a class="medical medical_review" href="/z/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia", section on 'Bruton tyrosine kinase inhibitors'</a>.)</p><p>Therapies that suppress T cell immunity also increase susceptibility to invasive fungal infections, including <em>Candida</em> and <em>Aspergillus</em> infections. Such regimens include intensive glucocorticoid therapy, use of antithymocyte globulin, <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, purine analogs (eg, <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>, <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">pentostatin</a>), and patients receiving chimeric antigen receptor-T cell therapies. (See  <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">"Glucocorticoid effects on the immune system", section on 'Infection risk'</a> and  <a class="medical medical_review" href="/z/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia"</a>.)</p><p class="headingAnchor" id="H69318194"><span class="h1">PROPHYLAXIS</span></p><p class="headingAnchor" id="H564717685"><span class="h2">Primary prophylaxis</span><span class="headingEndMark"> — </span>Primary prophylaxis involves the administration of an antimicrobial agent to prevent infection in patients at increased risk and who have not previously had the type of infection being targeted. The benefits of primary antifungal prophylaxis have been observed in multiple studies. Much of the emphasis historically has been on the prevention of <em>Candida</em> infections. However, studies of <em>Aspergillus</em> prevention have intensified in recent years.</p><p>A 2007 meta-analysis that included 64 randomized trials compared systemic antifungal prophylaxis (eg, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>) with a control arm (placebo, no intervention, or a nonsystemic antifungal agent such as <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">clotrimazole</a>) in cancer patients receiving myelosuppressive chemotherapy (predominantly for acute leukemia) or undergoing hematopoietic cell transplantation (HCT) [<a href="#rid28">28</a>]. In patients with acute leukemia, antifungal prophylaxis was associated with significant reductions in fungal-related mortality (relative risk [RR] 0.66, 95% CI 0.44-1.00) and documented invasive fungal infections (RR 0.69, 95% CI 0.53-0.90). However, antifungal prophylaxis was associated with only a nonsignificant trend toward a reduction in all-cause mortality (RR 0.88, 95% CI 0.74-1.06).</p><p>A 2012 meta-analysis that included 20 randomized trials compared mold-active prophylaxis with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis in patients with hematologic malignancy receiving chemotherapy (6 trials) or HCT recipients (14 trials) with the following results [<a href="#rid29">29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mold-active prophylaxis reduced the number of proven or probable invasive fungal infections compared with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis (RR 0.71, 95% CI 0.52-0.98).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mold-active prophylaxis reduced the risk of invasive aspergillosis compared with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis (RR 0.53, 95% CI 0.37-0.75).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mold-active prophylaxis reduced the risk of invasive fungal infection-related mortality compared with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis (RR 0.67, 95% CI 0.47-0.96).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no difference in overall mortality between patients who received mold-active prophylaxis and those who received <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mold-active prophylaxis was associated with an increased risk of adverse events leading to antifungal discontinuation (RR 1.95, 95% CI 1.24-3.07).</p><p></p><p class="headingAnchor" id="H1760179036"><span class="h3">Approach to primary prophylaxis</span><span class="headingEndMark"> — </span>The following recommendations represent our approach to antifungal prophylaxis in patients with hematologic malignancies. These recommendations are generally in keeping with the 2018 American Society of Clinical Oncology and Infectious Diseases Society of America (IDSA) antimicrobial prophylaxis guidelines for patients with cancer-related immunosuppression [<a href="#rid30">30</a>] and the 2016 IDSA guidelines for the diagnosis and management of aspergillosis [<a href="#rid31">31</a>].</p><p>It should be noted that there is ongoing controversy about the use of antifungal prophylaxis (see <a class="local">'Risk-benefit assessment'</a> below). In addition, the need for antifungal prophylaxis depends at least in part upon local rates of resistance as well as the overall risk of invasive fungal infections based upon which antineoplastic regimens are used. As a result, practices regarding antifungal prophylaxis differ widely at various cancer centers, and our approach may be different from the approach recommended at a specific institution.</p><p>We favor the following approach to primary antifungal prophylaxis in patients with acute leukemia [<a href="#rid30">30</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with acute leukemia undergoing initial-induction or salvage-induction chemotherapy who are expected to develop severe oral and/or gastrointestinal mucositis, we recommend prophylaxis against <em>Candida</em> infections. We prefer <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg orally once daily). A fluconazole dose of 200 mg once daily has also been studied [<a href="#rid32">32</a>], but we favor the 400 mg daily dose out of a theoretical concern that the lower dose could promote the development of resistance. Alternative agents include <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">micafungin</a>, <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">caspofungin</a>, and <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">anidulafungin</a>. (See <a class="local">'Candida infection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For selected patients who are expected to experience prolonged severe neutropenia (absolute neutrophil count [ANC] &lt;500 cells/microL for &gt;7 days) due to intensive chemotherapy for acute myelogenous leukemia (AML) or advanced myelodysplastic syndrome (MDS), we suggest prophylaxis against invasive mold infections and <em>Candida</em> spp with <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> rather than targeted anti-<em>Candida</em> prophylaxis with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> [<a href="#rid30">30,31</a>]. Patients undergoing induction therapy typically require one or two cycles of intensive chemotherapy, and clearance of leukemia is evaluated with a repeat bone marrow biopsy performed two weeks after the start of chemotherapy, which determines the need for a second course of chemotherapy. A threshold risk for invasive mold infection of &gt;6 percent (which is the estimated risk in those who require two cycles of chemotherapy) is generally considered as sufficient to justify anti-mold prophylaxis. Since the need for a second course of therapy is not known until two weeks after treatment starts and the risk of mold infections is very low during that interval, we typically start with fluconazole, and, if a second course of chemotherapy is needed, switch to voriconazole or posaconazole. An alternative for patients who cannot receive voriconazole or posaconazole is <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a>, although it has not been studied for prophylaxis in randomized controlled trials. (See <a class="local">'Aspergillus infection'</a> below.)</p><p></p><p class="bulletIndent1">We prefer the delayed-release <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> tablet (taken with food) over the oral suspension because it has more reliable oral absorption and achieves higher blood levels. Patients who are unable to take medications orally or who are expected not to absorb oral medications should be given intravenous (IV) posaconazole. Posaconazole delayed-release tablets should be given as a loading dose of 300 mg (three 100 mg tablets) every 12 hours on the first day, followed by a maintenance dose of 300 mg (three 100 mg tablets) daily starting on the second day. The IV formulation of posaconazole should be given as a loading dose of 300 mg every 12 hours on the first day, followed by a maintenance dose of 300 mg daily starting on the second day. The dosing of the oral suspension of posaconazole is 200 mg three times daily. The delayed-release tablets, the IV formulation, and the oral suspension should not be used interchangeably due to differences in dosing.</p><p></p><p class="bulletIndent1">The dosing of <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> is 200 mg orally twice daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antifungal prophylaxis is not recommended for patients in whom the anticipated duration of severe neutropenia is ≤7 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As there are many potential drug interactions between the extended-spectrum triazoles and drugs that may be used concomitantly, drug interactions should be taken into account before starting a triazole. (See <a class="local">'Drug interactions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because of inter-patient variability in drug levels, therapeutic drug monitoring of mold-active azoles should be done where possible [<a href="#rid31">31</a>]. Serum trough drug levels for the mold-active azoles antifungal agents as well as for potentially interacting drugs, such as the calcineurin inhibitors and other CYP3A4 substrates, is advised. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Serum drug concentration monitoring'</a>.)</p><p></p><p class="headingAnchor" id="H564717692"><span class="h3">Candida infection</span><span class="headingEndMark"> — </span>In the 2007 meta-analysis described above, antifungal prophylaxis resulted in a significant reduction in invasive <em>Candida</em> infections in patients with acute leukemia and HCT recipients (RR 0.31, 95% CI 0.23-0.41) [<a href="#rid28">28</a>]. In a subgroup analysis of patients with acute leukemia, the reduction in invasive <em>Candida</em> infections remained statistically significant.</p><p>Meta-analyses and randomized trials have determined that <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> is efficacious in preventing <em>Candida</em> infections in high-risk patients [<a href="#rid12">12,28,33,34</a>]. Infection rates at or above a threshold of 10 percent are seen primarily in patients undergoing intensive induction chemotherapy for AML with severe oral and/or gastrointestinal mucositis [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H69316976"><span class="h4">Choice of agent</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> has been studied most rigorously for <em>Candida</em> prophylaxis, other agents have also been evaluated and are considered acceptable alternatives, including <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">micafungin</a>, <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">caspofungin</a>, and <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">anidulafungin</a> [<a href="#rid30">30</a>].</p><p>When <em>Candida</em> prophylaxis is indicated, we favor <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>. Fluconazole has the advantage of being available as both oral and intravenous formulations, excellent tolerability, inexpensive generic formulations, and less severe interactions with concomitant medications compared with the extended-spectrum azoles.</p><p><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> has several important drawbacks, including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Its spectrum of activity against <em>Candida</em> spp is narrower than the echinocandins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breakthrough infections with fluconazole-resistant <em>Candida</em> species, especially <em>C. krusei</em> and <em>C. glabrata</em>, have been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> has no activity against <em>Aspergillus</em> or other molds in comparison with the other acceptable agents, which have at least some activity against <em>Aspergillus</em> spp.</p><p></p><p>Alternative agents have the following benefits and drawbacks:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echinocandins</strong> – The echinocandins (<a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">caspofungin</a>, <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">micafungin</a>, <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">anidulafungin</a>) have a broader spectrum of activity than <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, with most common <em>Candida</em> species being susceptible, and an excellent safety record. The drawbacks of this antifungal class are its availability only as an IV formulation and its high cost. (See  <a class="medical medical_review" href="/z/d/html/13945.html" rel="external">"Pharmacology of echinocandins and other glucan synthesis inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Voriconazole</strong> – <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> has both oral and IV formulations but has been noted to cause transient visual disturbances (that are not permanent or serious) and photosensitivity and may cause more hepatotoxicity than <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>. A major drawback is its potential interactions with certain chemotherapy agents. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Voriconazole'</a> and  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Voriconazole'</a> and <a class="local">'Drug interactions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posaconazole</strong> – <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">Posaconazole</a> was previously available only as an oral suspension. In 2013, delayed-release tablets became available and, in 2014, an IV formulation became available. It has been evaluated primarily for its anti-mold activity, but in trials low rates of <em>Candida</em> infections were noted, and posaconazole is therefore an option for prevention of yeast infections [<a href="#rid23">23</a>]. We prefer the oral delayed-release tablet over the oral suspension because it has more reliable oral absorption and achieves higher blood levels [<a href="#rid35">35,36</a>]. A drawback is its potential interactions with certain chemotherapy agents. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Itraconazole</strong> – <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> is available as an oral formulation; the intravenous formulation has been withdrawn in the United States but remains available in some countries. The oral formulation is relatively poorly tolerated and has variable bioavailability. Another major drawback is its potential interactions with certain chemotherapy agents. Itraconazole is used rarely given these limitations. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Itraconazole'</a> and <a class="local">'Drug interactions'</a> below.)</p><p></p><p class="headingAnchor" id="H564717699"><span class="h3">Aspergillus infection</span><span class="headingEndMark"> — </span>The need for <em>Aspergillus</em> prophylaxis for high-risk neutropenic patients varies according to the underlying disease and its therapy. Several trials suggest that the risk-benefit ratio favors prophylaxis when the rate of invasive aspergillosis is at least 6 percent [<a href="#rid23">23,37</a>]. <em>Aspergillus</em> prophylaxis has been demonstrated to be beneficial in patients with AML or MDS receiving induction chemotherapy [<a href="#rid23">23</a>].</p><p>The efficacy of antifungal agents with activity against <em>Aspergillus</em> spp and other molds (eg, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a>, and amphotericin B formulations) has been evaluated in various studies. A meta-analysis that compared mold-active prophylaxis with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis is discussed above [<a href="#rid29">29</a>]. (See <a class="local">'Primary prophylaxis'</a> above.)</p><p>All of the agents with activity against molds also have activity against <em>Candida</em> spp. We prefer either <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> for anti-mold prophylaxis in this patient population.</p><p class="headingAnchor" id="H18984029"><span class="h4">Posaconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">Posaconazole</a> is an extended-spectrum triazole with activity against <em>Aspergillus</em> spp and the agents of mucormycosis. Posaconazole was compared with the standard azole used at participating centers (<a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>) in a multicenter randomized open-label trial of 602 patients 13 years of age or older with prolonged neutropenia due to chemotherapy for AML or advanced MDS [<a href="#rid23">23</a>]. Prophylaxis was given with each cycle of chemotherapy until recovery from neutropenia and complete remission, occurrence of an invasive fungal infection, or for up to 12 weeks, whichever came first.</p><p><a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">Posaconazole</a> prophylaxis was associated with a significant reduction in proven or probable invasive fungal infections (2 versus 8 percent) that was due entirely to a reduction in invasive aspergillosis [<a href="#rid23">23</a>]. Posaconazole was also associated with a significant reduction in all-cause mortality (16 versus 22 percent). However, serious adverse events attributable to the drug were significantly more common with posaconazole (6 versus 2 percent), although the rate of toxicity of all causes was similar between the two groups [<a href="#rid23">23</a>]. It is not known whether the adverse events that were attributable to the study drug were more common in patients who received chemotherapy concomitantly with posaconazole.</p><p>As there are many potential drug interactions between the extended-spectrum triazoles and drugs that may be used concomitantly, drug interactions should be taken into account before starting a triazole. (See <a class="local">'Drug interactions'</a> below.)</p><p>It is important to note that the absorption of the oral suspension of <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> is greatly improved by concomitant food (especially high-fat food); if the patient is not eating, absorption is greatly impeded and it is unlikely that blood posaconazole levels will be adequate. For this reason, we prefer the delayed-release tablet due to its more reliable oral absorption [<a href="#rid35">35,36,38,39</a>]. The delayed-release formulation should be taken with food. Patients who are unable to take medications orally or who are expected not to absorb oral medications should be given IV posaconazole. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Posaconazole'</a>.)</p><p class="headingAnchor" id="H148200"><span class="h4">Voriconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> has activity against <em>Aspergillus</em> spp but not against the agents of mucormycosis. Although voriconazole is used in some centers, there are no large randomized trials evaluating the possible benefit of this agent for prophylaxis in patients with AML or MDS receiving induction chemotherapy. However, a large randomized trial was performed during the pre- and postengraftment period in HCT recipients, many of whom had AML [<a href="#rid40">40</a>]. Among patients who received voriconazole compared with those who received <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, fungal-free survival (the primary endpoint, defined as freedom from an invasive fungal infection or death at 180 days) was similar (78 versus 75 percent). There were trends toward fewer invasive fungal infections (7 versus 11 percent), <em>Aspergillus</em> infections (9 versus 17), and less frequent use of empiric antifungal therapy (24 versus 30 percent) in patients who received voriconazole compared with those who received fluconazole. In a post-hoc analysis of HCT recipients with AML, those who received voriconazole had significantly improved fungal-free survival (78 versus 61 percent) and significantly fewer invasive fungal infections (9 versus 21 percent), but no difference in overall survival (81 versus 72 percent) compared with those who received fluconazole. (See  <a class="medical medical_review" href="/z/d/html/16534.html" rel="external">"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients", section on 'Prophylaxis during the pre-engraftment period'</a>.)</p><p><a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> has been best evaluated for the treatment of invasive aspergillosis; it is the preferred agent for treatment. (See  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a>.)</p><p class="headingAnchor" id="H18984037"><span class="h4">Itraconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> has activity against <em>Aspergillus</em> spp. Two meta-analyses concluded that itraconazole was effective for preventing invasive fungal infections [<a href="#rid41">41,42</a>], but one found that the protective effect from prophylaxis was limited to trials using itraconazole oral solution (at a dose of 200 mg twice daily), a preparation that is poorly tolerated [<a href="#rid42">42</a>]. Itraconazole's absorption is greatly affected by the formulation (oral solution greater than oral capsule), gastric acidity, and concomitant food intake.</p><p>As there are many potential drug interactions between the extended-spectrum triazoles and drugs that may be used concomitantly, drug interactions should be taken into account before starting a triazole. (See <a class="local">'Drug interactions'</a> below.)</p><p class="headingAnchor" id="H18984053"><span class="h4">Amphotericin B</span><span class="headingEndMark"> — </span>Amphotericin B formulations have activity against <em>Aspergillus</em> spp and the agents of mucormycosis as well as <em>Candida</em> spp, but they are generally not used for antifungal prophylaxis due to their adverse effects and insufficient evidence regarding their efficacy. <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">Amphotericin B deoxycholate</a> given parenterally has been plagued by infusional toxicities and nephrotoxicity, and its efficacy as prophylaxis is not well established. Some studies in patients with hematologic malignancies have suggested a benefit of the prophylactic use of lipid formulations of amphotericin B given parenterally [<a href="#rid13">13,43,44</a>], whereas others have not [<a href="#rid45">45-47</a>]. Unfortunately, several trials were underpowered to provide definitive answers. The possible efficacy of lipid formulations of amphotericin B for antifungal prophylaxis has been insufficiently studied to date. Although the lipid formulations of amphotericin B are less toxic than amphotericin B deoxycholate, adverse effects are still substantial [<a href="#rid44">44,46,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Safety and efficacy'</a>.)</p><p>The efficacy of aerosolized <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> in preventing invasive pulmonary aspergillosis was evaluated in a randomized placebo-controlled trial of 271 patients with hematologic malignancies (during 407 neutropenic episodes) who were expected to be neutropenic for at least 10 days [<a href="#rid48">48</a>]. All patients received prophylaxis to prevent <em>Candida</em> infection. In the intent-to-treat analysis, aerosolized amphotericin B was associated with a significant reduction in the rate of invasive aspergillosis compared with placebo (4.3 versus 13.6 percent; odds ratio 0.26, 95% CI 0.09-0.72). No survival benefit was observed, but this study was probably underpowered to detect such an effect. There was a significantly greater incidence of adverse events, primarily cough, preventing adherence to the drug administration in a sizable proportion of patients.</p><p>Aerosolized amphotericin B has not been directly compared with systemic antifungal prophylaxis. Thus, additional studies are needed before this therapy can be recommended for patients who require antifungal prophylaxis. It is also important to note that droplet size is crucial to ensure delivery of the drug to the lower respiratory tract and may vary from one delivery device to another.</p><p>Amphotericin B or <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> given as an oral suspension or lozenge has had some benefit in reducing superficial infections (mostly <em>Candida</em>) in some (but not all) studies, but, overall, has not had a consistent benefit in reducing colonization and, more importantly, systemic or invasive infections [<a href="#rid49">49,50</a>]. This is not surprising since the usual portals of entry for <em>Aspergillus</em> spp and other molds are the sinuses and respiratory tract.</p><p class="headingAnchor" id="H1011023546"><span class="h4">Isavuconazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">Isavuconazole</a> has excellent anti-mold activity, has been found to be effective in treatment of both aspergillosis and mucormycosis, and has shown protective effects against mucormycosis in mice [<a href="#rid51">51</a>]. In a small phase II trial in patients with acute myelogenous leukemia undergoing induction therapy, isavuconazole prophylaxis was found to be well tolerated and reliably achieved trough serum concentrations of &gt;1 micrograms/mL, but reductions in some antileukemic agents were required due to avoid deleterious drug-drug interactions [<a href="#rid52">52</a>]. However, in one retrospective review of 145 patients with hematologic malignancies and HCT recipients, an increase in invasive fungal infections was observed when isavuconazole was used for primary prophylaxis compared with either <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> or <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> [<a href="#rid53">53</a>]. Nine invasive fungal infections occurred in patients receiving isavuconazole prophylaxis compared with three patients receiving posaconazole and one patient receiving voriconazole. Most infections were due to molds (eg, <em>Aspergillus, Fusarium, Rhizopus </em>spp) and occurred primarily in neutropenic patients undergoing chemotherapy for AML. Breakthrough infections have also been reported with isavuconazole prophylaxis in case series; however, the patient populations studied are often heavily treated, which may enhance the likelihood of this outcome [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H69317229"><span class="h3">Risk-benefit assessment</span><span class="headingEndMark"> — </span>Although antifungal prophylaxis has been proven to be efficacious in selected high-risk patients with hematologic malignancies, issues surrounding overuse of antifungal agents (eg, resistance, toxicity, and cost) and the relatively low incidence of invasive fungal infections in these patients have tempered enthusiasm for universal prophylaxis. The risk-benefit analysis must include an assessment of the relative level of immunosuppression and comorbidities to identify those individuals at increased risk for invasive fungal infections. The level of immunosuppression is higher after induction chemotherapy for acute leukemia compared with other settings, such as following consolidation chemotherapy. Important comorbidities include older age, the presence or absence of mucositis, poorly controlled diabetes, smoking history, iron overload from transfusions, and recurrent use of antibacterial agents.</p><p>Factors that support the use of antifungal prophylaxis in high-risk patients include the substantial morbidity and mortality of invasive fungal infections and the difficulty in obtaining a timely diagnosis due to the limitations of available diagnostic tests [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H564717720"><span class="h2">Secondary prophylaxis</span><span class="headingEndMark"> — </span>Patients who have a history of a prior invasive fungal infection, especially <em>Aspergillus</em> infections, are at high risk for recurrence of infection with further antileukemic therapy. This has been best studied in patients with prior <em>Aspergillus</em> infection. Continued treatment after initial control (so-called secondary prophylaxis) can prevent reactivation of infection in most patients and permit further antileukemic therapy [<a href="#rid31">31,55,56</a>].</p><p>For patients with a history of prior invasive aspergillosis receiving myelosuppressive chemotherapy with an anticipated prolonged neutropenic period of at least two weeks, we recommend antifungal prophylaxis with a mold-active agent [<a href="#rid57">57</a>]. The choice of agent depends in part upon the need to avoid drug interactions while chemotherapy is being given. <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> is the first-line agent for <em>Aspergillus</em> spp and has been best studied as secondary prophylaxis, but mold-active azoles are usually not given concomitantly with certain chemotherapy regimens containing agents metabolized in the liver. Of note, this is not a concern for agents such as <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a> or <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>. This is discussed in greater detail below. (See <a class="local">'Drug interactions'</a> below.)</p><p>For patients with prior <em>Candida</em> infections, secondary prophylaxis should be selected based on the <em>Candida</em> species and on which agent was successful in achieving earlier control.</p><p class="headingAnchor" id="H69317003"><span class="h2">Duration</span><span class="headingEndMark"> — </span>The duration of antifungal prophylaxis should be individualized based on the patient's clinical status and history of prior fungal infections [<a href="#rid57">57</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with acute leukemia, primary prophylaxis against molds and/or <em>Candida</em> spp is typically continued until myeloid reconstitution has occurred.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have a history of a prior invasive fungal infection who are receiving secondary prophylaxis during a period of myelosuppression (eg, during induction chemotherapy in AML patients), prophylaxis is usually continued at least until myeloid reconstitution has occurred. In such patients, follow-up imaging (computed tomography scan of the organ involved in prior infection) and fungal markers (eg, <em>Aspergillus</em> galactomannan antigen, beta-D-glucan) are often obtained two to four weeks after antifungal prophylaxis has been discontinued to ensure that reactivation has not occurred. Patients undergoing repeated courses of myelosuppressive chemotherapy should generally continue secondary prophylaxis until completion of the course of chemotherapy.</p><p></p><p class="headingAnchor" id="H69318399"><span class="h1">PRE-EMPTIVE THERAPY</span><span class="headingEndMark"> — </span>An alternative to antifungal prophylaxis involves pre-emptive therapy. This approach involves targeted screening of high-risk patients for markers of colonization and/or infection in an attempt to prevent invasive infection. Screening involves checking fungal markers, such as the <em>Aspergillus</em> galactomannan antigen, <em>Aspergillus </em>polymerase chain reaction (if available), and beta-D-glucan, and chest computed tomography scanning. This approach is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Pre-emptive therapy'</a>.)</p><p class="headingAnchor" id="H564717706"><span class="h1">BREAKTHROUGH INFECTIONS AND RESISTANCE</span><span class="headingEndMark"> — </span>Broad use of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> prophylaxis has led to increases in <em>Candida</em> species with reduced susceptibility or resistance to fluconazole (eg, <em>C. glabrata</em>, <em>C. krusei</em>) [<a href="#rid58">58,59</a>]. Cross-resistance to any azole may occur in <em>Candida</em> species, especially <em>C. glabrata</em> [<a href="#rid60">60,61</a>]. There has also been growing concern about the emergence of echinocandin resistance among <em>Candida</em> spp [<a href="#rid62">62</a>]. Thus, prophylaxis should be limited to those patients who are at substantial risk for invasive infection, and one should be mindful of the potential for breakthrough <em>Candida</em> infections, especially with <em>C. krusei</em> or <em>C.</em> <em>glabrata</em>. (See  <a class="medical medical_review" href="/z/d/html/2442.html" rel="external">"Candidemia in adults: Epidemiology, microbiology, and pathogenesis"</a>.)</p><p>An increase in mucormycosis has been reported in several retrospective studies of <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> prophylaxis in several centers [<a href="#rid63">63-65</a>], but, in prospective epidemiologic studies and in controlled prophylaxis trials, mucormycosis remains infrequent and no clear-cut association has been established between voriconazole prophylaxis and the development of mucormycosis. (See  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p>It is important to note that <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">caspofungin</a> and other echinocandins are not active against <em>Cryptococcus neoformans</em>, <em>Trichosporon</em>, <em>Fusarium</em>, or filamentous molds other than <em>Aspergillus</em>. In addition, some yeasts can demonstrate relative resistance to these drugs (<em>Candida parapsilosis</em>, <em>Candida rugosa</em>, <em>Candida guilliermondii</em>, and non-<em>Candida</em> yeasts). Failure of caspofungin to prevent aspergillosis has also been reported [<a href="#rid66">66</a>]. Moreover, the clinical efficacy of the echinocandins for endemic fungi (<em>Histoplasma capsulatum</em>, <em>Blastomyces dermatitidis</em>, <em>Coccidioides</em> spp) has not been demonstrated. In addition, some studies, mostly from one center, suggest an increase in mold infections with echinocandin prophylaxis relative to the mold-active azoles [<a href="#rid67">67</a>]. More data are needed. (See  <a class="medical medical_review" href="/z/d/html/2443.html" rel="external">"Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV"</a> and  <a class="medical medical_review" href="/z/d/html/2461.html" rel="external">"Diagnosis and treatment of disseminated histoplasmosis in patients without HIV"</a> and  <a class="medical medical_review" href="/z/d/html/2463.html" rel="external">"Treatment of blastomycosis"</a> and  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a> and  <a class="medical medical_review" href="/z/d/html/2449.html" rel="external">"Manifestations and treatment of nonmeningeal extrathoracic coccidioidomycosis"</a>.) </p><p>For suspected breakthrough mold infection in patients receiving mold-active azoles, a prompt and aggressive approach to establish a specific diagnosis is recommended [<a href="#rid31">31</a>]. Serum trough levels of the prophylactic azole should be obtained if possible. The patient should be changed to another class of anti-mold drug during the evaluation and immunosuppression reduced if feasible. If a breakthrough mold infection is diagnosed, antifungal susceptibility testing should ideally be considered. (See  <a class="medical medical_review" href="/z/d/html/465.html" rel="external">"Antifungal susceptibility testing"</a>.)</p><p class="headingAnchor" id="H564717713"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>There are many potential drug interactions between antifungal agents and drugs that may be used concomitantly [<a href="#rid68">68</a>]. Specific drug interactions unique to patients with hematologic malignancies are mentioned here.</p><p>The triazoles are metabolized by the cytochrome P450 isoenzymes, and there are multiple potential drug interactions:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> has been associated with a harmful interaction with <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, resulting in renal and hepatic toxicity [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> and <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> have been associated with severe neurotoxicity with <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">Itraconazole</a> has a potential negative inotropic effect and should be avoided in patients with prior congestive heart failure and drugs that could be cardiotoxic (eg, anthracyclines or high-dose <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> was associated with greater attributable drug toxicity than <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a> [<a href="#rid23">23</a>]. However, it is not known whether the adverse events were more common in patients who received chemotherapy concomitantly with posaconazole.</p><p></p><p>Given the potential for serious drug interactions, concomitant administration of extended-spectrum triazole-based prophylaxis (<a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>) should be avoided in patients receiving <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> or high doses of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>. Caution is advised for the concomitant use of the extended-spectrum triazoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes such as the tyrosine kinase inhibitors (eg, <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">nilotinib</a>). Of note, this is not a concern for agents such as <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a> or <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>.</p><p>Although drug-drug interactions related to cytochrome P450 metabolism appear less for <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a> than for <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> or <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, therapeutic drug monitoring of concomitantly administered drugs metabolized by cytochrome P450 may be prudent.</p><p>One tactic advised by some experts is to avoid administration of the extended-spectrum triazoles (<a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>) approximately one week before (to allow clearance) and during chemotherapy and then resume it after chemotherapy to avoid potential drug interactions; if interruption of antifungal drugs will pose a hazard to the patient, another class of antifungal agent (eg, amphotericin B or an echinocandin) can be given during the chemotherapy. Further study of the drug interactions between the extended-spectrum triazoles and chemotherapy drugs is necessary.</p><p>Combination prophylaxis with fluoroquinolones and triazoles is common and both classes have the potential to prolong the QTc interval and increase the risk for torsades de pointes. Other examples of important drug interactions between azoles and other drugs are provided in the table  (<a class="graphic graphic_table graphicRef66477" href="/z/d/graphic/66477.html" rel="external">table 1</a>). Drug interactions involving azoles are discussed in greater detail separately (see  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Drug interactions'</a>). Details about specific interactions may be obtained by using the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate.</p><p class="headingAnchor" id="H4064799990"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105460.html" rel="external">"Society guideline links: Neutropenic fever in adults with cancer"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/104073.html" rel="external">"Society guideline links: Invasive fungal infections"</a>.)</p><p class="headingAnchor" id="H564717764"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for invasive fungal infection </strong>–<strong> </strong>The<strong> </strong>risk for invasive fungal infections increases with the duration and severity of neutropenia, prolonged antibiotic use, and number of chemotherapy cycles. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candida infection </strong>– <em>Candida</em> is by far the most common fungal pathogen in patients with acute leukemia not receiving antifungal prophylaxis. Invasive candidiasis occurs most often as a result of translocation of colonizing <em>Candida</em> spp across the oral and/or gastrointestinal mucosa in the setting of mucositis from cytotoxic chemotherapy. Candidemia is the most frequent clinical manifestation of invasive candidiasis. Patients with acute leukemia are at highest risk for invasive candidiasis during induction chemotherapy. (See <a class="local">'Candida infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspergillus </strong>– <em>Aspergillus </em>is the most common mold pathogen in patients with acute leukemia. Its most common manifestation is pneumonia; less common manifestations include sinusitis and disseminated infection. (See <a class="local">'Aspergillus infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal prophylaxis </strong>–<strong> </strong>The following recommendations represent our approach to antifungal prophylaxis in patients with hematologic malignancies. It should be noted that there is ongoing controversy about the use of antifungal prophylaxis. As a result, practices regarding antifungal prophylaxis differ widely at various cancer centers, and our approach may be different from the approach recommended at a specific institution. (See <a class="local">'Approach to primary prophylaxis'</a> above and <a class="local">'Risk-benefit assessment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although antifungal prophylaxis has been proven to be efficacious in selected high-risk patients with hematologic malignancies, issues surrounding overuse of antifungal agents (eg, resistance, toxicity, and cost) and the relatively low incidence of invasive fungal infections in these patients have tempered enthusiasm for universal prophylaxis. The risk-benefit analysis must include an assessment of the relative level of immunosuppression and comorbidities to identify those individuals at increased risk for invasive fungal infections. (See <a class="local">'Risk-benefit assessment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with acute leukemia undergoing initial remission-induction or salvage-induction chemotherapy who are expected to develop severe oral and/or gastrointestinal mucositis, we recommend prophylaxis against <em>Candida</em> infections (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We prefer <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (400 mg orally once daily) for anti-<em>Candida</em> prophylaxis. (See <a class="local">'Approach to primary prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For selected patients who are expected to experience prolonged severe neutropenia (absolute neutrophil count [ANC] &lt;500 cells/microL for &gt;7 days) due to intensive chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome, we recommend prophylaxis against both invasive mold infections and <em>Candida</em> spp rather than targeted anti-<em>Candida</em> prophylaxis with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). In such patients, either <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> is an appropriate option as there is evidence of efficacy with both agents compared with other antifungal agents; these agents have not been compared directly to one another. When posaconazole is used, we prefer the delayed-release formulation rather than the oral suspension. The dosing of these agents is discussed above. Another alternative for patients who cannot receive posaconazole or voriconazole is <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a>, although it has not been studied for prophylaxis. (See <a class="local">'Approach to primary prophylaxis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a history of prior invasive aspergillosis receiving myelosuppressive chemotherapy with an anticipated prolonged neutropenic period of at least two weeks, we recommend secondary antifungal prophylaxis with a mold-active agent (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Secondary prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions </strong>– Given the potential for serious drug interactions, concomitant administration of extended-spectrum triazole-based (<a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>) prophylaxis should be avoided in patients receiving <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> or high doses of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>. Caution is advised for concomitant use of the extended-spectrum azoles with chemotherapy drugs metabolized by the liver, especially those metabolized by cytochrome P450 isoenzymes and other CYP3A4 substrates. (See <a class="local">'Drug interactions'</a> above.)</p><p></p><p class="headingAnchor" id="H2002773189"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kieren A Marr, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pfaffenbach B, Donhuijsen K, Pahnke J, et al. [Systemic fungal infections in hematologic neoplasms. An autopsy study of 1,053 patients]. Med Klin (Munich) 1994; 89:299.</a></li><li><a class="nounderline abstract_t">Cho SY, Choi HY. Opportunistic fungal infection among cancer patients. A ten-year autopsy study. Am J Clin Pathol 1979; 72:617.</a></li><li><a class="nounderline abstract_t">Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis 1966; 19:667.</a></li><li><a class="nounderline abstract_t">Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11:99.</a></li><li><a class="nounderline abstract_t">Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91:1068.</a></li><li><a class="nounderline abstract_t">Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91:986.</a></li><li><a class="nounderline abstract_t">Donhuijsen K, Petersen P, Schmid WK. Trend reversal in the frequency of mycoses in hematological neoplasias: autopsy results from 1976 to 2005. Dtsch Arztebl Int 2008; 105:501.</a></li><li><a class="nounderline abstract_t">Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845.</a></li><li><a class="nounderline abstract_t">Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112:2493.</a></li><li><a class="nounderline abstract_t">Cornely OA, Gachot B, Akan H, et al. Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis 2015; 61:324.</a></li><li><a class="nounderline abstract_t">Wirk B, Wingard JR. Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. Mycopathologia 2009; 168:299.</a></li><li><a class="nounderline abstract_t">Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28:331.</a></li><li><a class="nounderline abstract_t">Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17:1306.</a></li><li><a class="nounderline abstract_t">Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28:250.</a></li><li><a class="nounderline abstract_t">Nucci M, Biasoli I, Akiti T, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30:300.</a></li><li><a class="nounderline abstract_t">Wingard JR, Vaughan WP, Braine HG, et al. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am J Med 1987; 83:1103.</a></li><li><a class="nounderline abstract_t">Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495.</a></li><li><a class="nounderline abstract_t">Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995; 20:115.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851.</a></li><li><a class="nounderline abstract_t">Wingard JR. Zygomycosis: epidemiology and treatment options. Proceedings of Johns Hopkins Advanced Studies in Medicine 2006; 6:S526.</a></li><li><a class="nounderline abstract_t">Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16:607.</a></li><li><a class="nounderline abstract_t">Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient. Oncology (Williston Park) 2001; 15:351.</a></li><li><a class="nounderline abstract_t">Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348.</a></li><li><a class="nounderline abstract_t">Lortholary O, Gangneux JP, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect 2011; 17:1882.</a></li><li><a class="nounderline abstract_t">Pagano L, Akova M, Dimopoulos G, et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 2011; 66 Suppl 1:i5.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110:1303.</a></li><li><a class="nounderline abstract_t">Tisi MC, Hohaus S, Cuccaro A, et al. Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study. Haematologica 2017; 102:e108.</a></li><li><a class="nounderline abstract_t">Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25:5471.</a></li><li><a class="nounderline abstract_t">Ethier MC, Science M, Beyene J, et al. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. Br J Cancer 2012; 106:1626.</a></li><li><a class="nounderline abstract_t">Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 2018; 36:3043.</a></li><li><a class="nounderline abstract_t">Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.</a></li><li><a class="nounderline abstract_t">MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002; 112:369.</a></li><li><a class="nounderline abstract_t">Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89:1611.</a></li><li><a class="nounderline abstract_t">Bow EJ, Laverdière M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002; 94:3230.</a></li><li><a class="nounderline abstract_t">Cumpston A, Caddell R, Shillingburg A, et al. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. Antimicrob Agents Chemother 2015; 59:4424.</a></li><li><a class="nounderline abstract_t">Kersemaekers WM, Dogterom P, Xu J, et al. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother 2015; 59:3385.</a></li><li><a class="nounderline abstract_t">Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335.</a></li><li class="breakAll">Noxafil (posaconazole) injection for intravenous use, delayed-release tablets for oral use, oral suspension, prescribing information. https://www.merck.com/product/usa/pi_circulars/n/noxafil/noxafil_pi.pdf (Accessed on March 18, 2014).</li><li><a class="nounderline abstract_t">Krishna G, Ma L, Martinho M, O'Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 2012; 56:4196.</a></li><li><a class="nounderline abstract_t">Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116:5111.</a></li><li><a class="nounderline abstract_t">Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005; 131:22.</a></li><li><a class="nounderline abstract_t">Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21:4615.</a></li><li><a class="nounderline abstract_t">Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev 2014; :CD000026.</a></li><li><a class="nounderline abstract_t">Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2014; :CD000969.</a></li><li><a class="nounderline abstract_t">Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23:163.</a></li><li><a class="nounderline abstract_t">Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31:135.</a></li><li><a class="nounderline abstract_t">Timmers GJ, Zweegman S, Simoons-Smit AM, et al. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000; 25:879.</a></li><li><a class="nounderline abstract_t">Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46:1401.</a></li><li><a class="nounderline abstract_t">Cornely OA, Böhme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009; 94:113.</a></li><li><a class="nounderline abstract_t">Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev 2014; :CD002033.</a></li><li><a class="nounderline abstract_t">Gebremariam T, Alkhazraji S, Baldin C, et al. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Bose P, McCue D, Wurster S, et al. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis 2021; 72:1755.</a></li><li><a class="nounderline abstract_t">Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Clin Infect Dis 2020; 70:723.</a></li><li><a class="nounderline abstract_t">Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 2018; 67:1610.</a></li><li><a class="nounderline abstract_t">Karp JE, Burch PA, Merz WG. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am J Med 1988; 85:203.</a></li><li><a class="nounderline abstract_t">Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33:943.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.</a></li><li><a class="nounderline abstract_t">Wingard JR, Merz WG, Rinaldi MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274.</a></li><li><a class="nounderline abstract_t">Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37:1847.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42:3142.</a></li><li><a class="nounderline abstract_t">Tsai HF, Bard M, Izumikawa K, et al. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob Agents Chemother 2004; 48:2483.</a></li><li><a class="nounderline abstract_t">Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis 2015; 61 Suppl 6:S612.</a></li><li><a class="nounderline abstract_t">Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950.</a></li><li><a class="nounderline abstract_t">Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350.</a></li><li><a class="nounderline abstract_t">Madureira A, Bergeron A, Lacroix C, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007; 30:551.</a></li><li><a class="nounderline abstract_t">Gomes MZ, Jiang Y, Mulanovich VE, et al. Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. Antimicrob Agents Chemother 2014; 58:2775.</a></li><li><a class="nounderline abstract_t">Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 2010; 53:95.</a></li><li><a class="nounderline abstract_t">Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103:1557.</a></li><li><a class="nounderline abstract_t">Pana ZD, Roilides E. Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma. Pediatr Blood Cancer 2011; 57:30.</a></li></ol></div><div id="topicVersionRevision">Topic 16141 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8072452" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : [Systemic fungal infections in hematologic neoplasms. An autopsy study of 1,053 patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/495566" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Opportunistic fungal infection among cancer patients. A ten-year autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5229422" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Fungal infections complicating acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1396746" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fungal infections in cancer patients: an international autopsy survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885047" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757415" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19626203" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trend reversal in the frequency of mycoses in hematological neoplasias: autopsy results from 1976 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1542320" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412153" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870323" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19247798" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10064252" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16766594" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10064240" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10671332" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3332568" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8442620" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7727637" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Importance of Candida species other than C. albicans as pathogens in oncology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852735" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Zygomycosis in the 1990s in a tertiary-care cancer center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Zygomycosis: epidemiology and treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14624113" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11301832" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Empiric antifungal therapy for the neutropenic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251531" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668573" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177404" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17614303" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27856512" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17909198" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22568999" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30179565" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27365388" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904111" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11013378" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115356" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25987632" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25824210" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251530" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17251530" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22615291" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20826719" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16173959" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14673051" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25188768" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Routine versus selective antifungal administration for control of fungal infections in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25188673" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10197802" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162375" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10808210" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419443" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19066334" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25188770" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Nystatin prophylaxis and treatment in severely immunodepressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28264840" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32236406" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30958538" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29771293" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3165248" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15034546" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1669837" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239594" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243073" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215098" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26567278" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Echinocandin Resistance in Candida.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14985500" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356827" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15776383" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029149" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590477" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20002883" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clinically relevant drug interactions of current antifungal agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504090" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cyclophosphamide metabolism is affected by azole antifungals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21265011" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
